Monoclonal Gammopathy of Thrombotic Significance
American Journal of Hematology · 2026-10 · 101 (10) · 2616-2631
DOI: 10.1002/ajh.70467 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 09.08.2026. Verfasst von Matthew Ho und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Thrombosis, Monoclonal Gammopathy of Undetermined Significance, Paraproteinemias. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHGRI NIH HHS, National Human Genome Research Institute.
Abstract (Originalsprache)
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant precursor to multiple myeloma (MM). While development of end‐organ damage in MM largely reflects increasing clonal burden, emerging evidence indicates that qualitative properties of the monoclonal immunoglobulins in MGUS can be directly pathogenic, leading to serious organ injury independent of disease burden. This has led to the recognition of a broader spectrum of disorders collectively termed monoclonal gammopathy of clinical significance (MGCS). MGCS can be further subclassified based on the organ system involved; for example, monoclonal gammopathy of renal significance specifically refers to monoclonal immunoglobulin‐driven renal injury. Along these lines, we propose monoclonal gammopathy of thrombotic significance (MGTS) as encompassing thrombotic disorders in which there is definitive, mechanistically supported evidence that a monoclonal (M)‐protein associated with a clonal plasma or B‐cell disorder directly contributes to thrombosis. Based on current evidence, monoclonal protein–induced immune thrombocytopenia and thrombosis is the only disorder that meets our criteria for MGTS. Other thrombotic disorders, such as thrombotic microangiopathy and antiphospholipid syndrome, may occur in the setting of a monoclonal protein and have biologically plausible M‐protein‐mediated mechanisms; however, direct evidence implicating the M‐protein in thrombosis is currently lacking. Accordingly, we provisionally classify these disorders as thrombotic syndromes associated with M‐proteins, pending causal validation. We also highlight thrombotic disease associations with multifactorial pathogenesis that should not be classified as MGTS. Broader recognition of MGTS is essential to advance consensus definitions, establish diagnostic criteria, and develop evidence‐based management strategies for this clinically important group of disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Matthew Ho, S Vincent Rajkumar
Förderung
- NHGRI NIH HHS
- National Human Genome Research Institute
Zitieren
APA
Ho, M., Zanwar, S., Kumar, S., & Rajkumar, S. V. (2026). Monoclonal Gammopathy of Thrombotic Significance. American Journal of Hematology, 101(10), 2616-2631. https://doi.org/10.1002/ajh.70467
Vancouver
Ho M, Zanwar S, Kumar S, Rajkumar SV. Monoclonal Gammopathy of Thrombotic Significance. American Journal of Hematology. 2026;101(10):2616-2631. doi:10.1002/ajh.70467
BibTeX
@article{Ho2026,
author = {Ho, Matthew and Zanwar, Saurabh and Kumar, Shaji and Rajkumar, S Vincent},
title = {Monoclonal Gammopathy of Thrombotic Significance},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {10},
pages = {2616--2631},
doi = {10.1002/ajh.70467}
}
EUVIMED